维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

16篇 您的检索式：作者名="Piermarocchi"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A oneyear follow-up controlled study显示文摘AIM:To evaluate the efficacy and safety of a combined treatment for myopic choroidal neovascularization(CNV)using photodynamic therapy(PDT)and intravitreal bevacizumab and to compare it with intravitreal bevacizumab monotherapy.METHODS:Thirty-four eyes with angiographic evidence of myopic CNV were randomly divided into two groups:17 were treated with one intravitreal bevacizumab injection(1.25 mg)and low-fluence-rate PDT within seven days of the injection(Group A).The other 17 received monotherapy with bevacizumab injections(Group B).Clinical evidence of complications,best corrected visual acuity(BCVA)and fluorescein leakage were evaluated.BCVA and optical coherence tomography(OCT)were evaluated monthly.The timepoints follow-up was established at 6 and 12mo.All patients were retreated following a PRN protocol.RESULTS:A total of 34 eyes of 34 patients(26 women and 8 men)with a mean age of 62.35 years were included.In Group A(17 eyes)the mean BCVA increased from 0.55±0.13 logMAR before the treatment to 0.40±0.09 logMAR at the 12mo follow-up(P<0.01).In Group B(17 eyes)the mean BCVA increased from 0.60±0.11 logMAR before the treatment to 0.55±0.12 logMAR at the 12mo follow-up(P<0.01).There was no statistically significant difference between the two groups in terms of LogMar visual acuity.In Group A the mean number of combined treatments was 1.8±0.11 per patient;in Group B the mean number of intravitreal bevacizumab injections was3.1±0.08 per patient.The number of treatments was significantly fewer in Group A(P<0.01).No local or systemic side effects occurred among any of the patients treated in this study.CONCLUSION:The combination of anti-angiogenic injections and PDT appears to be a safe and effective option for myopic CNV treatment and allows for a significant reduction of intravitreal injections.	Sandro Saviano Rita Piermarocchi Pia E.Leon Alessandro Mangogna Andrea Zanei Fabiano Cavarzeran Sc Daniele Tognetto	2014	International Journal of Ophthalmology(English edition)2014，7，2：	5
	2	Carotenoids and antioxidants in age-related mae ulopathy Italian study: Multifocal electroretinogram modifications after 1 year 显示文摘	Parisi V Tedeschi M Gallinaro G Varano M Saviano S Piermarocchi S	2008	Ophthalmology2008，115，3：	1
	3	Efficacy and safety of anti-vascular endothelial growth factor(VEGF) therapy with in- travitreal ranibizumab (Lucentis) for naive retinal vein occlu- sion: 1-year follow-up 显示文摘	Pece A Isola V Piermarocchi S Calori G	2011	Br J Ophthalmol2011，95，1：	1
	4	Theory of Quantum Optical Control of a Single Spin in a Quantum Dot显示文摘	Chen P C Piermarocchi C Sham L J	2004	Phys Rev B2004，69，07：	1
	5	Efficacy and safety of anti-vascular endothelial growth factor(VEGF)therapy with intravitreal ranibizumab(Lucentis)for naive retinal vein occlusion:1-year follow-up显示文摘	Pece A Isola V Piermarocchi S	2011	Br J Ophthalmol2011，95，1：	1
	6	Efficacy and safety of an- ti-vascular endothelial growth factor(VEGF)therapy with intravit- real ranibizumab(Lucentis)for naive retinal vein occlusion: 1- year follow-up显示文摘	Pete A Isola V Piermarocchi S	2011	Br Jophthalmol2011，95，1：	1
	7	Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion:1-year follow-up显示文摘	Pece A Isola V Piermarocchi S	2011	Br J Ophthalmol2011，95，1：	1
	8	Retinopathy following radiation therapy of paranasal sinus and nasopharyngeal carcinoma显示文摘	Midena E Segato T Piermarocchi S	1987	Retina1987，7，3：	1
	9	Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreat ranibizamab (Lucentis) for naive retinal vein occlusion 1-year follow-up 显示文摘	Pece A Isola V Piermarocchi S	2011	Br J Ophthalmol2011，95，1：	1
	10	Efficacy and safty of anti-vascular endothelial growth factor(VEGF) therapy with in- travitreal ranibizumab ( Lucentis ) for naive retinal vein occlu- sion: 1-year follow-up 显示文摘	Pece A Isola V Piermarocchi S Calori G	2011	Br J Ophthalmol2011，95，1：	1
	11	Efficacy and safety of anti-vas- cular endothelial growth factor(VEGF) therapy with intravitreal ranibi- zumab ( Lucentis ) for naive retinal vein occlusion : 1-year follow-up 显示文摘	Pece A Isola V Piermarocchi S	2011	Ophthalmol2011，95，：	1
	12	Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab(Lucentis) for naive retinal vein occlusion:1-year follow-up显示文摘	Pece A Isola V Piermarocchi S		0，，01：	1
	13	Efficacy and safety of antivascular endothelial growth factor(VEGF)therapy with intravitreal ranibizumab for naive retinal vein occlusion:1–year follow-up显示文摘	Pece A Isola V Piermarocchi S	2011	Br J Ophthalmol2011，95，1：	1
	14	Combination ofphotodynamic therapy and intraocular triamcinolone for exudativeage-related macular degeneration and long-term chorioretinal macu-lar atrophy 显示文摘	Piermarocchi S Sartore M Lo Giudice G	2008	Arch Ophthalmology2008，126，10：	1
	15	Efficacy and safety of anti-vascular endothelial growth factor (vegf) therapy with intravitreal ran~bizuinab (lueentis) for naive retinal vein occlusion: 1-year follow-up 显示文摘	PECE A ISOLA V PIERMAROCCHI S CALORI G	2011	Br d Ophthal- mol2011，95，1：	1
	16	Efficacy and safety of an- ti-vascular endothelial growth factor (VEGF) therapy with intra- vitreal ranibizumab (Lucentis) for naive retinal vein occlusion :1 year follow-up显示文摘	Pece A Isola V Piermarocchi S	2011	Br J Ophthalmol2011，95，1：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费